RSC Drug Discovery

Emerging Drugs and Targets for Alzheimer's Disease

Complete Set

Ana Martinez (Editor)
ISBN: 978-1-84973-045-7
Copyright: 2010
Format: Hardback
Extent: 668
Price:  £220.00

Synopsis

Alzheimer´s disease (AD) is the most prevalent neurodegenerative disorder in the elderly. The Bloomberg School of Public Health recently estimated that over 26 million people were living with AD in 2006 and that the number will grow to 106 million by 2050. Interventions that delay onset by just one year could reduce the 2050 figure by 12 million. This demonstrates the importance and social need of finding an effective therapeutic intervention.

Both volumes gather together some of the most promising examples of drugs now in pharmaceutical development, and new targets currently going through a validation process. It describes the discovery and development history of the disease modifying therapeutics most likely to reach the Alzheimer´s market in the next few years. It will be of interest to both those working in the pharmaceutical industry and in academia from graduate level onwards.

Author Information

Ana Martinez obtained her PhD in Organic Chemistry from the Complutense University of Madrid before becoming a researcher at the Medicinal Chemistry Institute of the Spanish National Council for Research (CSIC). Since 1995, her interests have focused on neurodegenerative disorders and she has led numerous research projects on the medicinal chemistry and rational drug design with the aim of finding new treatments for Alzheimer's disease. In February 2002, she joined NeuroPharma (now NOSCIRA) as R&D Director where she led projects from the discovery of potential new therapies to the final proof of concept in animal models. In February 2008, she returned to her academic position at the Medicinal Chemistry Institute (CSIC) leading several projects on neurodegenerative disease therapies and acting as an external scientific advisor to a number of pharmaceutical companies. Her main areas of research currently involve GSK-3 inhibitors and dual binding site acetylcholinesterase inhibitors. She has authored over a hundred and fifty scientific publications and has more than twenty active patents in the field.